Sarah Sammons/medicine.duke.edu
Jun 3, 2025, 13:23
Sarah Sammons: RLY2608 and Fulvestrant in HR+/HER2- PIK3CA mutant breast cancer
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared on X:
“Major unmet need for Mutant Specific PIK3CA inhibitors with improved efficacy and side effects for our patients.
RLY2608 and Fulvestrant in post-CDK4/6 HR+, HER2- PIK3CA mutant breast cancer.
ORR close to 40% post-CDK4/6.
Median PFS 10 months all comers, 11 months 2L, 18 months kinase mutant.
Side effects mostly low grade: hyperglycemia, nausea, fatigue. Little rash, oral mucositis, diarrhea.
Phase III opening at sites next week!”
You can find more posts featuring Sarah Sammons on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 22, 2025, 13:38
Jul 22, 2025, 13:21
Jul 22, 2025, 12:56
Jul 22, 2025, 12:42
Jul 22, 2025, 12:15
Jul 22, 2025, 11:56